Kornimate/medical-research-clean huggingface dataset:
does apoe-e4 predict delirium and cognitive dysfunction after surgery?

Conditions: Delirium; Postoperative Cognitive Dysfunction

Summary: patients with the apoe-ε4 genotype are at increased risk of both vascular dementia and peripheral vascular disease. patients undergoing major vascular surgery are at particularly high risk of delirium and other, more subtle, changes in cognitive function following surgery. the hypothesis of this trial is that the apoe-ε4 genotype is associated with both delirium and postoperative cognitive dysfunction (pocd).


Eligibility criteria:
inclusion criteria: * age 60 or greater * open repair of the abdominal aorta exclusion criteria: * refusal; * planned endovascular repair; * emergency surgery; * previous diagnosis of dementia, parkinson's disease, or psychiatric illness; * active alcohol or substance abuse; and * physical inability to complete neuropsychometric testing.

Keywords: delirium (mesh unique id d003693) cognition disorders (mesh unique id d003072) postoperative complications (mesh unique id d011183) apolipoproteins e (mesh unique id d001057)
laparoscopic revision gastric bypass for inadequate initial weight loss

Conditions: Inadequate Initial Weight Loss; Persistent Clinically Severe Obesity

Summary: the main aim of this study is to analyze and report traditional, patient-centered, and composite intermediate-term outcomes after laparoscopic revision roux-en-y gastric bypass surgery for inadequate initial weight loss.

there is lack of standardization of primary and revisional bariatric surgery compounded by a scant long-term outcome data. the treatment of inadequate weight loss, weight recidivism, and most severe technical complications after primary bariatric surgery remains refractory to non-operative treatment. failure rates have been reported up to 20% and 35% for the morbidly obese (mo) and super obese (so), respectively at 2 to 3 years after surgery. the indication for further surgical intervention remains controversial, as does what type of revisional procedure, both operative and endoscopic, to recommend. furthermore, there is no standardization of the limb lengths, pouch size or the use of prosthetic reinforcement. therefore the approach to these patients must be as individualized as their original operations. we formally analyze our experience with all laparoscopic revisional strategies for inadequate initial weight loss after failed roux-en-y gastric bypass(rygb).

Eligibility criteria:
inclusion criteria: * laparoscopic revisional rygb for failed rygb with iiwl or non-responders pattern exclusion criteria: * failed rygb with a wr pattern * patients with prior major bariatric conversion or esophago-gastric surgeries * rygb patients revised by an open surgical approach * rygb patients who underwent laparoscopic revisional rygb surgery somewhere else and continue their follow-up care with program * missing records and/or unreachable patients with scan information for analysis

Keywords: inadequate initial weight loss inadequate weight loss poor weight loss failed gastric bypass revision gastric bypass
adoption of audio recording in the outpatient supportive care center

Conditions: Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Recurrent Malignant Solid Neoplasm

Summary: this study evaluates how patients feel about having an audio recording of their visit to help remember information given to them and share that information with family members and/or caregivers not present during a clinic visit. information from this study may help evaluate the effectiveness of using technology to help improve patient care by recording consultation recommendations.

primary objective: i. to assess the patient's perception of the usefulness of the audio recording in helping to recall information given to him/her in the visit along with the perception of usefulness in the dissemination of information to family member(s) and/or caregiver(s) not present at the clinic visit. secondary objectives: i. to assess the number of times the recording is listened to. ii. to assess the ease of use of the technology. iii. to assess the ability to share the information with the patient's family member(s) and/or caregiver(s) if he or she chooses to do so. iv. to assess the patient perception of whether the audio recording caused any disruption to the clinic. v. to estimate the participation rate of patients. vi. to explore association between patient's perception of the usefulness of the audio recording and patient's demographic/clinical characteristics. vii. to explore the association between age and sex of the caregiver and frequency of caregiver's use of the audio recording. viii. to explore the association of the ease of use of the technology and the type of device and application used. outline: patients audio record the recommendations and instructions given to them by the doctor record as part of their clinic visit at the supportive care center.

Eligibility criteria:
inclusion criteria: * patients with the diagnosis of advanced cancer as defined as locally advanced, recurrent or metastatic cancer. both solid and liquid tumors are eligible for the study * patients who are seen in the outpatient supportive care center at m.d. anderson cancer center * patients who have access to a recording device or cellphone with recording technology * patients who can be contacted 7 to 11 days from the clinic visit that the recording took place * patients who can sign informed consent * patients who are able to read and write in english * patients 18 years or older exclusion criteria: * patients who have been diagnosed with delirium or cognitive impairment. this will be defined by chart review along with review of the md anderson symptom inventory (mdas) the day of clinic visit. an mdas of 7 or greater will be considered to define delirium in this study * patients who are unwilling to sign informed consent * patients who have used audio recordings before in clinic visits * patients who have severe hearing impairments without access to assisted devices or programs to aid in listening to the recorded material
community activation for prevention (caps): a study of community gardening

Conditions: Cancer; Obesity; Lifestyle, Sedentary; Physical Activity; Health Behavior; Chronic Disease; Diet Modification

Summary: the investigators previous studies show that community gardening is associated with reduction of key health behaviors for cancer prevention in diverse populations. community gardeners eat more fruits and vegetables per day, are more physically active, and are more likely to avoid age-associated increase in body mass index (bmi). the effect is partially explained by the finding that gardeners are more socially involved, and feel more social support than non-gardeners. the investigators propose a randomized controlled trial to determine whether community gardening improves cancer-preventive behaviors among a multi-ethnic, low-income adult population and elucidate the pathways that shape cancer-preventive behaviors. a randomized controlled trial is needed to demonstrate that the observed behavioral differences are due to the effect of gardening as an intervention rather than self-selection by gardeners.


Eligibility criteria:
inclusion criteria: * able to give informed consent in english or spanish * aged 18 or over * currently on the wait list for a new garden * not have gardened in the past 2 gardening seasons exclusion criteria: * is not able to complete the study requirements in spanish or english * aged 17 or younger * has gardened in the past 2 gardening seasons

Keywords: randomized controlled trial community gardening health behavior change physical activity diet obesity cancer prevention neighborhood
evaluation of efficacy and safety of atb-1011+atb-1012 co-administration for essential hypertension and type ii diabetes

Conditions: Essential Hypertension; Diabetes Mellitus, Type 2

Summary: the purpose of this study is to evaluate safety and efficacy of atb-1011 and atb-1012 co-administration in patients with essential hypertension and type ii diabetes mellitus

primary objectives: * to demonstrate superiority of 12-week co-administration of atb-1011 and atb-1012 in blood pressure control over atb-1012 monotherapy * to demonstrate superiority of 12-week co-administration of atb-1011 and atb-1012 in diabetes control over atb-1011 monotherapy

Eligibility criteria:
inclusion criteria: * those with primary hypertension and type ii diabetes mellitus (dm) * those who have been given adequate explanation about the purpose and the details of the clinical trial and have given voluntary, written informed consent * those who have not taken any antihypertensive agents for ≥2 weeks prior to randomization. * those who have not taken any oral hypoglycemic agents, except for same dose of metformin (≥1000 mg/day), for ≥8 weeks prior to randomization exclusion criteria: * those with reference arm mean sitting diastolic blood pressure (msdbp) ≥110 mmhg at screening or at randomization * those with differences of systolic blood pressure (sbp) ≥ 20 mmhg and diastolic blood pressure (dbp) ≥ 10 mmhg between arms measured 3 consecutive times with ≥2 minutes between each measurement at screening * those with a history of alcohol or substance abuse * those who are pregnant or nursing * those who have received other clinical trial drugs within 12 weeks prior to screening * those who are deemed ineligible to participate in the clinical trial based on the medical opinion of the investigator
subchondral microfracture of tibia after arthroscopic anterior cruciate ligament surgery reconstruction

Conditions: Anterior Cruciate Ligament Reconstruction; Subchondral Microfractures of Tibia

Summary: the arthroscopic anterior cruciate (acl) ligament reconstruction surgery is widespread. the creation of the tibial tunnel, retrograde or antegrade, is not consensual. a cadaveric study demonstrated tibial subchondral microfractures in the group "antegrade tibial tunnel" unlike group "retrograde tibial tunnel." to our knowledge, no clinical evaluation was performed. the investigators hypothesize that retrograde drilling will cause less local bone injury than antegrade drilling in creation of the tibial tunnel for acl reconstruction.


Eligibility criteria:
inclusion criteria: * arthroscopic reconstruction surgery of an anterior cruciate ligament tear exclusion criteria: * previous reconstruction of acl * associated lesions (meniscal tear, other ligament...) * refusal consent
brinzolamide/brimonidine twice a day (bid) fixed combination (fc) vs brinzolamide bid and brimonidine bid in patients with open angle glaucoma or ocular hypertension

Conditions: Open-Angle Glaucoma; Ocular Hypertension

Summary: the purpose of this study was to evaluate the safety and efficacy of brinzolamide/brimonidine in lowering intraocular pressure (iop) relative to each of its individual active components in patients with open-angle glaucoma or ocular hypertension.

this study consisted of 7 visits conducted during 2 sequential phases: the screening/eligibility phase, which included a screening visit and 2 eligibility visits, and a treatment phase, which included 4 on-therapy visits conducted at week 2, week 6, month 3, and month 6 (or early exit). following washout of any iop-lowering medication, subjects who met all inclusion/exclusion criteria at both eligibility visits and who had iop measurements within the specified range during this period were randomized to 1 of 3 study drug groups: brinz/brim, brinz, or brim.

Eligibility criteria:
inclusion criteria: * diagnosed with open angle glaucoma or ocular hypertension, and, in the opinion of the investigator, are insufficiently controlled on monotherapy or are currently on multiple iop-lowering medications. * meet qualifying iop entry criteria. * able to understand and sign an informed consent form. * other protocol-specified inclusion criteria may apply. exclusion criteria: * women of childbearing potential if pregnant, test positive for pregnancy at screening visit, breastfeeding, or not in agreement to use adequate birth control methods to prevent pregnancy throughout the study. * severe central visual field loss. * best corrected visual acuity (bcva) score worse than 55 etdrs letters (20/80 snellen equivalent). * chronic, recurrent or severe inflammatory eye disease. * ocular trauma within the preceding 6 months. * ocular infection or ocular inflammation within the preceding 3 months. * clinically significant or progressive retinal disease. * other ocular pathology. * intraocular surgery within the 6 months prior to entry. * ocular laser surgery within the 3 months prior to entry. * any abnormality preventing reliable applanation tonometry. * any other conditions, including severe illness, which would make the subject, in the opinion of the investigator, unsuitable for the study. * recent use of high-dose (\>1 gram daily) salicylate therapy. * recent, current, or anticipated treatment with any medication that augments adrenergic responses, or precludes use of an alpha-adrenergic agonist. * concurrent use of glucocorticoid medications administered by any route. * other protocol-specified exclusion crtieria may apply.

Keywords: open-angle glaucoma ocular hypertension oag oht
an acupuncture study for breast cancer survivors with joint pain on hormonal therapies

Conditions: Breast Cancer; Breast Cancer Female; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer Stage IIIB; Breast Cancer Stage IIIc; Breast Cancer, Male

Summary: the purpose of this study is to see whether acupuncture is a practical (feasible) treatment for breast cancer survivors with joint pain on hormonal therapies.


Eligibility criteria:
inclusion criteria: * english- or spanish-speaking * black, asian, and/or hispanic women with a history of stage i, ii, or iii bc (transgender males are eligible to enroll) * no evidence of current bc disease * receiving ai for at least 28 days with plan to continue for another 14 weeks * worst pain rated ≥4 on a 0-10 scale in the preceding week * ≥15 days with pain in the past 30 days * pain lasting ≥1 month * pain attributed to ai as reported by the patient * willing and able to complete questionnaires and other study activities * willing and able to provide informed consent for the trial exclusion criteria: * all stage iv cancer * active oncological disease * completed chemotherapy, surgery, or radiation \<4 weeks prior to study * pain attributed to inflammatory arthritis (e.g., rheumatoid arthritis, gout) * procedures involving affected joints within the last month or planned in the next 14 weeks * acupuncture use for pain in the past year * implanted electronic device (e.g., pacemaker)

Keywords: history of breast cancer breast cancer stage i breast cancer stage ii breast cancer stage iii breast cancer stage iiib breast cancer stage iiic acupuncture breast cancer
the efficacy of dexamethasone versus dexamethasone combined with rituximab in patients with newly diagnosed idiopathic thrombocytopenic purpura (itp)

Conditions: Idiopathic Thrombocytopenic Purpura

Summary: in this study we want to investigate if combination therapy with rituximab (r) + dexamethasone (dxm) is superior to monotherapy with dxm in patients with newly diagnosed idiopathic thrombocytopenic purpura (itp). before treatment molecular studies - gene expression profiling - are performed to characterize at the molecular level those patients responding adequately to the treatment as compared to those obtaining a minor or no responses. the hypothesis is that combination therapy is superior to monotherapy as defined above. using gene expression studies up-front the hypothesis is that this method may be able to predict the response to treatment.


Eligibility criteria:
inclusion criteria: * age 18 years or over * diagnosis = itp + platelet count above or equal to 25 mia/l or platelet count above or equal to 50 mia/l and bleeding from the mucous membranes. * adequate contraceptive measures within the last 3 months for women of childbearing potential. exclusion criteria: * performance status above or equal to 2 * previous treatment with rituximab * immunosuppressive treatment within the last month except for not previously treated patients * other serious disease * pregnant women and nursing mothers * contraindication for rituximab treatment. * active infection requiring antibiotic treatment.

Keywords: itp-rituximab-dexamethasone
study of light treatment and laser treatment for melasma

Conditions: Melasma

Summary: the purpose of this study is to determine the efficacy of light treatment and laser treatment for melasma. these treatment options have not been thoroughly explored in the treatment of melasma. by studying the effect of different treatments, a better treatment plan may be developed for people with melasma.

the objective of this study is to determine the efficacy of light treatment and laser treatment for melasma. these treatment options have not been thoroughly explored in the treatment of melasma. by studying the effect of different treatments, a better treatment plan may be developed for people with melasma.

Eligibility criteria:
inclusion criteria: * diagnosis of melasma lesion measuring at least 4 square centimeters. * age 18-75 years. * good health. * willingness and ability to understand and provide informed consent for participation in the study. * ability to communicate with the investigator. * must be willing to forgo other treatment options for melasma during the course of the study. exclusion criteria: * inability to understand the protocol or to give informed consent. * mental illness. * under 18 years of age and over 75 years of age. * laser treatment in the last 6 months before enrollment. * isotretinoin within the past year. * lidocaine allergy. * history of herpes simplex viral infection. * concurrent active disease to facial area (i.e acne). * bleeding disorder. * history of abnormal wound healing. * history of abnormal scarring.
ani-guided fentanyl infusion during living donor liver resections

Conditions: No Disease or Condition is Being Studied

Summary: thу goal of this study was to learn whether intraoperative analgesia nociception monitoring (ani) could be beneficial during intraoperative monitoring for patients undergoing living donor liver resections. the main questions it aims to answer are: * could it impact the average dose of intraoperative fentanyl used? * could it impact the occurrence of postoperative nausea and vomiting? patients who were included in this study underwent living liver donor resections with fentanyl infusion and thoracic epidural analgesia. two groups of patients were analysed - the ani group (n = 24), in which fentanyl dose was adjusted with ani monitoring, and the retrospective control group (n = 25) with a standard practice without ani monitoring.

monitoring nociception accurately during general anaesthesia has presented a long-standing difficulty. typically, anaesthesiologists rely on changes in the autonomic nervous system, such as heart rate, blood pressure, and sweating, to help determine the need for pain relief medication. analgesia nociception index (ani) is a noninvasive tool for monitoring the intraoperative state of the autonomic nervous system, particularly the parasympathetic nervous system. during the long-lasting high nociceptive surgery, the infusion of fentanyl was used at our institution. opioids can lead to postoperative nausea, vomiting, and other complications when an overdose occurs. fentanyl dosage changes significantly after hours of infusion due to context-sensitive halftime. it is practically impossible to adjust an infusion dose with the subjective evaluation of standard monitoring, such as heart rate and blood pressure. doses of opioids that we use in our daily practice, e.g. mcg.kg-1, are unpredictable and vary between individuals due to pharmacogenetics and pharmacokinetic reasons. the best method to exclude pharmacokinetic peculiarities and predict the subsequent dose is to directly measure analgesic agents' concentration in the blood, though it is practically impossible. this study aimed to assess whether intraoperative analgesia nociception monitoring (ani) could have an impact on the average intraoperative dose of fentanyl and on the occurrence of postoperative nausea and vomiting.

Eligibility criteria:
inclusion criteria: * female and male patients, 18 - 60 years old, undergoing living donor liver resections with general anaesthesia with sevoflurane, thoracic epidural analgesia and fentanyl on infusion. asa i, ii exclusion criteria: * patients with cardiac arrhythmia (atrial fibrillation, frequent extrasystoles - more than one extrasystole in 30 seconds), total intravenous anaesthesia with propofol
propolis in the treatment of periodontitis

Conditions: Chronic Periodontitis

Summary: this study was conducted to evaluate by clinical and microbiological parameters the effect of locally delivered propolis as an adjunct to scaling and root planing in the treatment of chronic periodontitis.

materials and methods: 20 subjects diagnosed with chronic periodontitis were recruited to participate in split-mouth design and provided informed consent. subgingival plaque sampling and clinical recording at baseline, 15 days and 1 month was performed. the patients received scaling and root planing, followed by propolis administration subgingivally in the test sites. significant differences between test and control were evaluated using the mann-whitney u test and wilcoxon rank test.

Eligibility criteria:
inclusion criteria: * good general health * chronic periodontitis * minimum of 20 natural teeth with at least one pocket per quadrant * probing depth (pd) between 5 and 8 mm. exclusion criteria: * subgingival instrumentation within 3 months * antibiotic therapy within 3 months prior to the start of the study; * smokers * pregnant or nursing women * intolerance or allergy to honey products
iron therapy in colo-rectal neoplasm and iron deficiency anemia: intravenous iron sucrose versus oral ferrous sulphate.

Conditions: Colorectal Neoplasm; Iron Deficiency Anemia

Summary: the main objective of this study is to evaluate the efficacy of intravenous iron sucrose in increasing preoperative haemoglobin values in patients with colo-rectal neoplasm and iron deficiency anemia, compared to the standard treatment with oral iron. it will also determine whether intravenous iron sucrose administration improves outcomes such as postoperative haemoglobin values, serum ferritin values, transfusional needs, postoperative complications, or length of hospital stay.

most patients with colorectal neoplasm have iron deficiency, which can be triggered in the pre-operative period by a decrease of iron intake and the bleeding in the site of neoplasm. in the postoperative period, iron deficiency can be aggravated by surgical bleeding. iron plays a leading rol in haemoglobin production, cell mitosis and immune system. animal experimentation has shown that induced iron deficiency and mild anemia lead to postoperative mortality and lactacidemia in a model of peritonitis. moreover, anemia is the main risk factor to require intra and postoperative blood transfusions, and iron deficiency and anemia are associated to a larger number of postoperative complications (infections and longer hospital stay). oral iron therapy is the standard treatment in patients with preoperative iron deficiency, but iron levels inside red cells may not reach normality in time before surgery, and it can not be resumed until the patient can start again oral feeding. in these patients, any increase in preoperative haemoglobin decreases the risk to need a blood transfusion during or after surgery. this trial will compare standard oral iron and intravenous iron.

Eligibility criteria:
inclusion criteria: * non-recurrent colorectal neoplasm, surgically resectable * anemia exclusion criteria: * severe renal impairment * high anesthetic risk